Novel compounds to treat urinary tract infection [abstract]

Abstract

Urinary tract infections (UTI) affect a large proportion of the population and account for significant morbidity and high medical costs. Uropathogenic Escherichia coli (UPEC) is responsible for up to 85% of infections and a large percentage of recurrent UTI are caused by the same strain of bacteria as the initial UTI despite the antibiotic regimen; the current gold standard. The annual UTI incidence rate is 12.1% in women and 3% among men. Recurrence rates are high with women having a 25% to 44% chance of developing a second episode within 6 months of the initial UTI. Treatment of UTI like other microbial infections is exacerbated by increasing antimicrobial resistance and there is a huge unmet need for alternative therapies. Novel patented compounds such as Pilicides and Mannosides disrupt pili biogenesis and host-pathogen interaction to effectively block disease progression. Potential Areas of Applications: * Urinary tract Infections

Patent Status: * Pilicides : Issued Patents 7,411,066 B2, 7,041,465, and 6,495,539 * Mannosides : provisional patent on file

Inventor(s): Scott Hultgren, Fred Almqvist, Jim Janetka, Jerry Pinkner Contact Info: Leena Prabhu, Ph.D. MBA lprabhu@wustl.edu (314)-747-1906